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ABSTRAK 
Kajian ini bertujuan untuk menentukan peranan 18F-Fluorodeoxyglucose FDG 
PET-CT untuk mengesan kanser kolorektal yang berulang serta mengkaji faktor yang 
mungkin mempengaruhi prestasi diagnostik PET-CT. Satu kajian retrospektif yang 
diluluskan oleh lembaga etika daripada University Sains Malaysia dan Jawatankuasa 
Etika & Penyelidikan Perubatan (MREC) telah dijalankan di Institut Kanser Negara 
Putrajaya di antara Januari hingga Disember 2014, melibatkan kesemua pesakit 
kanser kolorektal yang pernah dirawat dan dirujuk untuk ujian PET-CT atas sebab 
disyaki penyakit berulang berdasarkan paras CEA atau pengimejan CT skan. Imej-
imej PET-CT dinilai oleh seorang pakar perunding perubatan nuklear. Histopatologi, 
pengimejan atau susulan klinikal sekurang-kurangnya enam bulan diguna sebagai 
standard rujukan untuk mengenalpasti diagnosis akhir. 16 daripada 85 pesakit 
dikecualikan daripada analisis sebab maklumat susulan tidak diperolehi. Daripada 69 
pesakit yang dianalisa (lelaki: perempuan = 41:28), kanser berulang dikesan dalam 
39.1%. Sensitiviti, spesifisiti, nilai ramalan positif, nilai ramalan negatif dan ketepatan 
PET-CT ialah 92.6%, 88.1%, 83.3%, 94.9% dan 89.9% masing-masing. PET-CT 
mempunyai prestasi diagnostik yang tinggi untuk menilai pesakit dengan paras CEA 
tinggi dan pesakit dengan penemuan mencurigakan pada CT skan. Ia lebih tepat 
daripada CT skan dalam mengesan lokasi benar kanser berulang dan dapat mengesan 
lebih banyak lokasi metastasis. Pesakit dengan tahap CEA semakin meningkat tetapi 
masih dalam had normal dan CT skan normal mempunyai risiko kanser berulang yang 
rendah (0% dalam kajian ini) dan kemungkinan pengimejan PET-CT adalah tidak 
diperlukan. Kesimpulannya, PET-CT adalah sensitif dan spesifik dalam mengesan 
kanser kolorektal berulang.  
	 x	
ABSTRACT 
Title: The Role Of FDG PET-CT In Detection Of Recurrent Colorectal Cancer 
In National Cancer Institute, Putrajaya, Malaysia 
This study aimed to determine the role of 18F-Fluorodeoxyglucose (FDG) 
PET-CT in detection of recurrent colorectal cancer in our institution as well as to 
correlate factors which may influence diagnostic performance of PET-CT. An Ethics 
Board (from Universiti Sains Malaysia and Medical Research & Ethics Committee, 
MREC) approved retrospective study was performed in National Cancer Institute, 
Putrajaya from January to December 2014, recruiting all consecutive patients with 
treated colorectal cancer and was suspected to have recurrence based on CEA levels 
or CT imaging. PET-CT images were reviewed by a dedicated senior nuclear 
medicine consultant. Histopathology or clinical and imaging follow up for at least six 
months were used as reference standard to confirm the final diagnosis. 16 of 85 
patients recruited were excluded from analysis due to unavailability of follow up data. 
In the other 69 patients (M:F = 41:28), recurrence was diagnosed in 39.1%. 
Sensitivity, specificity, positive predictive value, negative predictive value and 
accuracy of PET-CT in detecting recurrent colorectal cancer in this study were 92.6%, 
88.1%, 83.3%, 94.9% and 89.9% respectively. PET-CT had high diagnostic 
performance to evaluate patients with elevated CEA levels and with suspicious CT 
findings. It was more accurate than CT in detecting the true locations of recurrence 
and could detect more sites of recurrence. Patients with rising CEA level but still 
within normal limit and normal CT imaging had low risk of recurrence (0% in this 
study) and were likely not indicated for PET-CT imaging. In conclusion, PET-CT is 
sensitive and specific in detecting recurrent colorectal cancer.  
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CHAPTER 1 
INTRODUCTION 
1.1 EPIDEMIOLOGY OF COLORECTAL CANCER: 
Colorectal cancer (CRC) is a major global health problem. It is the third most 
common cancer in men after lung and prostate cancers and the second most prevalent 
cancer in women following breast cancer. According to GLOBOCAN database 2012, 
the highest incidence of CRC in Australia/ New Zealand (Age Standardized Rate, 
ASR of cancer incidence 44.8 and 32.2 per 100,000 in men and women) is almost ten 
times the incidence in South Africa (4.5 and 3.8 per 100,000 in men and women). In 
general, CRC is two to three folds more prevalent in the well developed nations than 
in developing nations. ASR in developing countries is 13.6 and 9.8 per 100,000 in 
men and women (Ferlay et al., 2015). Being a developing country, Malaysia has ASR 
of 13.4 and 10.2 per 100,000 in men and women respectively (based on Malaysia 
Cancer Statistics 2007) which is very similar to the global data. 
A very interesting change in the incidence rate of CRC has been observed over 
the last few decades. While many countries are enduring annual increase of CRC 
burdens, the incidence rate of CRC is actually decreasing in many developed 
countries such as United States of America, Western European countries and Japan. 
In fact, the incidence rate of CRC in USA declines by an astonishing rate of 3% each 
year from 2000 to 2010 (Siegel et al., 2014). This achievement is attributable to 
extensive availability of colonoscopy facilities and timely treatment of premalignant 
polypoidal lesions, which has been shown to prevent CRC (Winawer et al., 1993). 
Consistent with higher incidence rate of CRC, the ASR of CRC mortality is 
also higher in more developed regions of the world (14.4 and 9.3 per 100,000 in men 
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and women respectively) as compared to the less developed regions (7.8 and 5.6 per 
100,000 in men and women) (Ferlay et al., 2015). Nevertheless, more than 50% of 
these cancer deaths occur in developing countries.  
Malaysia Cancer Statistics 2007 reveals that our ASR of CRC mortality is 
9.39 per 100,000. The patient survival is highly dependent on the TNM staging. 
Proportions of Malaysian patients presenting in Stage I to Stage IV cancers are 9%, 
28%, 31% and 32% respectively and 5-year survival of each successive stage is 79%, 
65%, 44% and 9.3% respectively (Kong et al., 2010). 
Risk factors leading to development of CRC in a patient has been extensively 
researched. In the oncogenesis of CRC, environmental factors play a more dominant 
role than genetic mutations, which are mostly sporadic with minority of patients 
having hereditary disorders. The culprit environmental risk factors that have been 
identified include sedentary lifestyles, obesity, excessive red meat consumption, 
smoking and diabetes (Watson and Collins, 2011). 
 
1.2 OVERVIEW OF MANAGEMENT OF COLORECTAL CANCER: 
 The optimal treatment for CRC aims at curative surgical resection of the 
primary tumour and the regional draining lymph nodes that could harbour metastatic 
tumour cells. Complete mesocolic resection with removal of at least 12 lymph nodes 
is recommended as the standard surgical procedure for all patients (Benson et al., 
2014). Post-surgical treatments involving adjuvant chemotherapy and radiotherapy 
may be required depending on histopathology of the tumour, TNM staging and other 
risk factors such as bowel obstruction on presentation, DNA microsatellite instability 
(MSI) and chromosomal instability.  
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 Recurrence is a major issue following curative treatment determining ultimate 
survival of the patients. The reported overall recurrence rate ranges 25 – 40% and it is 
more common in the first two to three years post treatment (Steele et al., 2015).  
International guidelines that are published by American Society of Clinical Oncology 
(ASCO), National Comprehensive Cancer Network (NCCN) and European Society of 
Medical Oncology (ESMO) recommend routine use of clinical examination, 
colonoscopy, carcinoembryonic antigen (CEA) measurement and CT imaging for 
surveillance post treatment but recommended intervals to perform these tests are 
slightly different among these guidelines.  
Evidence supporting use of these routine investigations is provided by a study 
which showed that 63% of recurrences were first detected by rising CEA levels, 25% 
by imaging and 8% by clinical symtopms alone (Jochmans et al., 2008). Another 
study also demonstrated that follow up using CT imaging and frequent CEA 
measurements enabled earlier detection of recurrence by 8.5 months (p < 0.001) and 
improved detection rate of isolated local recurrence (p = 0.011) (Renehan et al., 2002). 
In a randomised controlled trial, CEA measurement 3-monthly for 2 years followed 
by 6-monthly for 3 years detected recurrences with a median lead time of 6 months 
(range 1 – 30 months) (McCall et al., 1994). 
Early detection of recurrence by active surveillance strategy has positive 
impact on patients’ survival. Reduction of all-cause mortality (combine risk ratio 0.81, 
p = 0.007) was shown in a study (Renehan et al., 2002) whereas improvement of 
overall survival (OR=0.73; 95% CI 0.59 to 0.91) was demonstrated in another meta-
analysis (Jeffery et al., 2007). The improved survival is due to increased likelihood of 
curative surgery in patients owing to early detection of recurrence. A randomised 
controlled trial assigned 1202 participants to 1 of the 4 groups for follow-up: CEA 
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only, CT only, CEA and CT or minimum follow up. After mean follow up of 4.4 
years, recurrences detected in the first 3 groups were at least 3 times more likely to be 
amenable to surgical treatment with curative intent compared with minimum follow 
up group (Primrose et al., 2014). 
Even though it is without doubt that surveillance is beneficial to CRC patients 
post treatment, sometimes inconsistent tests results may make the clinical decision of 
recurrent disease difficult. The examples include elevation of CEA when all other 
investigations are negative or CT findings suspicious of recurrence while CEA level 
is normal. These are common scenario in our local setting and 18F-
Fluorodeoxyglucose PET-CT is often utilised for further assessment. 
Management of recurrent colorectal cancer is best done in multi-disciplinary 
approach. Curative resection may be performed for locoregional recurrence and 
limited liver metastasis. Non-resectable metastatic disease may be treated with 
chemotherapy or biological targeted agents (monoclonal antibodies against vascular 
endothelial growth factor, VEGF or epidermal growth factor receptor, EGFR) (Van 
Cutsem et al., 2014). 
 
1.3 FUNDAMENTALS OF 18F-FLUORODEOXYGLUCOSE PET-CT: 
 Positron emission tomography (PET) is one of the nuclear medicine imaging 
modalities that provides functional and molecular imaging. PET technology first 
emerges in 1950s due to contributions by Gordon Brownell and others in 
Massachusetts General Hospital. Development of 18F-Fluorodeoxyglucose (FDG) by 
Al Wolf and Joanna Fowler in Brookhaven Laboratory, United States is another 
important milestone in PET imaging. 
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Unlike other nuclear medicine imaging utilising gamma emission 
radionuclides, PET uses positron emiting radioisotopes which include commonly used 
18Fluorine, 11Carbon, 13Nitrogen, 15Oxygen and 82Rubidium. In PET, radioactivity of 
administered radiotracer is localised by coincidence detection of 511keV annihilation 
photons directing at 180° apart along the line of response. In recent years, image 
quality has been improved by using photon detector with higher spatial and timing 
resolutions (e.g. LYSO) as well as more sophisticated processing using time of flight 
technology (TOF). Hybrid imaging combining PET with CT or even MRI is another 
major breakthrough in PET imaging (Lewellen, 2008). CT and MRI images provide 
attenuation correction for PET images and improve accuracy of PET by providing 
anatomical correlations. 
The physical half-lives of PET radioisotopes that range from few seconds to 
several hours, have huge impact on their availability and usage in various nuclear 
medicine centres across the world. 18F with its physical half-life of 110 minutes is the 
ideal radioisotope that can be produced in a regional cyclotron facility and 
subsequently be distributed to several nuclear medicine centres. This has helped to 
contain the cost of running PET imaging facilities, making PET imaging more 
affordable for the patients. 
 PET radiopharmaceuticals are used to target various biological processes of 
interest, such as metabolism of glucose, amino acid, phospholipid, nucleic acid as 
well as expressions of various receptors and hormones. Among them, glucose 
metabolism is the most studied metabolic pathway with its wide indications in both 
oncologic and non-oncologic diseases. 18F-Fluorodeoxyglucose (FDG) is a glucose 
analogue, which is taken intracellularly through glucose transporters (GLUT) via 
facilitated diffusion. Once the FDG is within the cytoplasm, it is phosphorylated by 
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hexokinase but unlike glucose FDG is not further metabolised along the glycolytic 
pathway. Hence, the phosphorylated FDG is trapped intracellularly and its bio-
distribution can be visualised by PET imaging.  
 Abnormal glucose metabolism in pathological conditions has been described 
as Warburg effect, in which there is overexpression of GLUT-1 and hexokinase 
resulting in increased glucose uptake by various oncogenic cells as well as activated 
leucocytes. Specifically for cancer cells, it has been discovered that increase in 
glucose metabolism is only part of the complex oncogenesis process which involves 
but not limited to oncoprotein expression, activation of tyrosine kinase activity, 
mitochondrial dysfunction, activation of proliferative cascades, angiogenesis, 
inhibition of apoptosis pathway and so forth. (Hagland et al., 2013)  
 
1.4 CLINICAL USE OF PET-CT: 
Direct imaging of pathological glucose metabolism, which occurs in various 
diseases, provides useful clinical information. Hence, PET-CT has been used widely 
for many clinical indications, which include staging of malignancy, restaging after 
neoadjuvant therapy, monitoring of treatment response and detection of recurrence. In 
some malignancies such as lymphoma, PET-CT has surpassed CT imaging as the 
imaging modality of choice for staging and monitoring of treatment response. Early 
treatment response monitoring provided by PET-CT enables individualised treatment 
strategy so that treatment efficacy is optimised while minimising treatment related 
complications (Johnson et al., 2015).  
 In the management of CRC, the currently recommended indications of PET-
CT is to investigated unexplained elevation of CEA when other imagings are negative 
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or equivocal, as well as restaging of patients before surgical resection of limited liver 
metastasis (Evidence-based indications for the use of PET-CT in the UK, 2012). 
 However, in our local experience the degree of CEA elevation when PET-CT 
should performed is variable, which may be influenced by the individual institution 
protocol, clinicians’ and also patients’ preferrences. It is also done when CEA is 
increasing trend but still within the normal range. 
 
1.5 RATIONALE OF THIS STUDY: 
Characteristics and risk of recurrence of patients with suspected recurrent 
CRC who are referred for PET-CT in our institution may be different from other 
study populations. Hence, diagnostic performance of PET-CT in our institution may 
also be different from other studies. Information about diagnostic performance of a 
test is essential to guide clinicians in selecting appropriate test for their patients.  
Besides that, when the clinical suspicion of recurrent CRC is based on rising 
trend of CEA levels, there is limited data from previous studies with regards to 
appropriate CEA threshold when PET-CT should be performed. As the result, we 
have observed considerable variation of CEA levels in patients referred for PET-CT 
in our institution. 
In addition, correlation between diagnostic performance of PET-CT with 
various demographic and clinical characteristics of patients are also studied with the 
intention to find more criteria that could assist in patient selection for PET-CT when 
recurrent CRC is suspected.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 FDG PET-CT IN DETECTION OF RECURRENT COLORECTAL 
CANCER: 
PET-CT is useful in detection of local recurrence of CRC as well as regional 
or distant metastasis. With regards to its role in detection of local recurrence, a study 
has shown that PET-CT can diagnose peri-anastomotic recurrence with high 
sensitivity and specificity of 100% and 97.1% respectively and in this study local 
recurrence was associated with peri-anastomotic or eccentric mass on CT (Shyn et al., 
2010). However, results of specificity of PET-CT are not consistent across the 
previous studies. Kau et al. (2009) has demonstrated in their cohort of 341 rectal 
cancer patients that even though PET/CT can detect local recurrence with high 
sensitivity of 100%, specificity is limited with the result of 64% (Kau et al., 2009). 
Direct comparison of PET-CT and CT has shown that PET-CT detects more 
lesions in patients with recurrent colorectal cancer. In a study by Yoon et al. (2011), 
PET-CT detected 27 additional lesions in 8 patients, comprising 9 seeding peritoneal 
nodules and 18 lymph nodes while both PET-CT and CECT successfully identified 
other 38 lesions in 12 patients; PET-CT was also superior to CECT in detecting 
subcentimeter lesions in pelvic cavities (Yoon et al., 2011).  
Diagnostic performance of PET-CT and CT is also compared in several other 
studies. In a retrospective study of 50 post treatment CRC patients with elevated CEA 
levels to compare performance of PET-CT and contrast-enhanced CT (CECT) in 
detection of recurrent disease, the result revealed that PET/CT has higher sensitivity 
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than CECT (97.3% and 70.3% respectively) (Metser et al., 2010). In this study, 
lesions correctly identified by PET-CT and missed by CECT were local recurrence in 
presacral space, metastasis in subcentimeter lymph nodes, peritoneal deposits and 
recurrence at periphery of radiofrequency ablated metastatic hepatic lesions. 
Han et al. (2011) performed another study in 66 patients and also showed 
superiority of PET-CT as compared to CT in detection of recurrence (sensitivity, 
specificity of 96.3%, 94.9% and 70.4%, 82.6% respectively) (Han et al., 2011). In this 
study, it was also demonstrated that mean SUVmax for malignant and benign lesions 
were  8.06 and 2.82 respectively. 
Another study of 170 patients also demonstrated that PET-CT had higher 
sensitivity than CECT (98% versus 82%) in detection of recurrent CRC, particularly 
in detecting local recurrence (100% versus 35%) and lymph nodes metastasis (100% 
versus 39%) (Deleau et al., 2011).  
High diagnostic performance of PET-CT to detect recurrent or metastatic CRC 
in patients with elevated CEA was confirmed by a meta-analysis of 11 studies that 
showed pooled sensitivity and specificity of 90.3% and 80.0% respectively (Lu et al., 
2013). A more recent meta-analysis combining data from 26 individual studies to 
ascertain diagnostic performance of PET-CT in detecting local recurrence showed 
high pooled sensitivity and specificity of 94.0% and 94.0% respectively, with overall 
diagnostic accuracy index of 0.9329 (Yu et al., 2015). 
 MRI is another clinical imaging modality that has advantages of avoiding 
ionising radiation and confering high soft tissue contrast. With advancement of 
technology such as parallel imaging which significantly reduces image acquisition 
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time, whole-body MRI has emerged as a valuable alternative in screening and 
detecting recurrent cancers.  
In a retrospective study to compare diagnostic accuracy of whole-body MRI 
and PET-CT to detect recurrent CRC, it was demonstrated that both whole-body MRI 
and PET-CT are equally sensitive to detect local recurrence and organ metastases; 
however PET-CT is more sensitive than whole-body MRI to detect lymph node 
metastasis (93% versus 63%) (Schmidt et al., 2009).  
 A separate study comparing diagnostic accuracy of whole-body diffusion-
weighted MRI with 3.0 T and PET-CT in detecting primary and metastatic neoplasms 
also demonstrated similar sensitivities of both modalities (Akay et al., 2013). Even 
though whole-body MRI is an attractive alternative to detect recurrent CRC, it also 
suffers from significant drawback of high cost and limited availability. 
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2.2 CORRELATION OF PET-CT AND FACTORS AFFECTING ITS 
DIAGNOSTIC PERFORMANCE: 
 Several studies have been done to investigate relationship between CEA and 
PET-CT in detection of recurrent CRC. A study conducted by Choi et al. (2005) 
observed a significant positive linear correlation between CEA and metabolic tumour 
volume on PET-CT (Choi et al., 2005). Besides that, Kyoto et al. (2010) also 
demonstrated that CEA levels significantly correlated with the tumour volumes (r = 
0.500, p < 0.001) (Kyoto et al., 2010). 
Due to the relationship between CEA and tumour volume on PET-CT, it is 
expected that PET-CT would have higher sensitivity to detect recurrent disease in 
patients with higher CEA levels. This is substantiated by a study of 73 post-operative 
CRC patients with various degrees of CEA elevation and the study result revealed that 
sensitivity of PET-CT increased from 53% in the group with CEA of 3 to 5 ng/ml to 
100% in the group with CEA of > 50 ng/ml (Mittal et al., 2011).  
A lesion-based analysis study of 106 post-operative patients with suspected 
recurrence found that PET-CT had sensitivity, specificity, and accuracy of 97.8%, 
82.6%, and 95.6% for patients with abnormal CEA levels, compared with 81.3%, 
80%, and 80.6% for patients with normal CEA levels and the difference was 
statistically significant (Zhang et al., 2014).  
However, there are also two studies which showed similar performance of 
PET-CT in detecting recurrence irrespective of the CEA levels. In one of the study, 
235 patients were subdivided into normal CEA (< 5 ng/ml) and elevated CEA (> 5 
ng/ml) groups and the result revealed that PET-CT had similar sensitivity, specificity 
of 100%, 84% and 97.1%, 84.6% respectively in the two groups (Sanli et al., 2012). 
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However, in this study, both groups had high percentage of recurrence, 64.4% for 
normal CEA group and 88% for elevated CEA group. 
In the other study, 69 patients were grouped according to CEA levels (5 to 9.9 
ng/ml, 10 to 14.9 ng/ml and > 15 ng/ml) and the results showed that sensitivity, 
specificity of PET-CT in each group were 100%, 60%; 100%, 75% and 95%, 62% 
respectively and the difference between the groups was not statistically significant 
(Ozkan et al., 2012b). 
 Extensive literature search did not find studies that attempt to correlate other 
possible factors that may influence diagnostic performance of PET-CT. Hence, this 
study would have added value in attempting to determine whether the diagnostic 
performance would differ in accordance to patients’ demographic  and clinical 
characteristics. 
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CHAPTER 3 
STUDY OBJECTIVES 
 
3.1 GENERAL OBJECTIVE: 
 This study intends to evaluate the role of PET-CT to detect recurrent CRC in 
National Cancer Institute, Malaysia. 
 
3.2 SPECIFIC OBJECTIVES: 
1. To determine diagnostic performance of PET-CT in detecting recurrent CRC. 
2. To correlate factors affecting diagnostic performance of PET-CT in detecting 
recurrent CRC. 
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CHAPTER 4 
METHODOLOGY 
 
4.1 PATIENT: 
This study included all consecutive patients with stage I to III (based on 
American Joint Committee on Cancer, AJCC TNM staging system) histologically 
proven CRC patients with no age limit and completed primary treatment with curative 
intent, which included compulsory surgery with or without chemotherapy and 
radiotherapy. Patients with distant metastases at presentation, recent chemotherapy or 
surgery less than 1 month, recent radiotherapy less than 3 months, history of other 
primary malignancies were excluded. Post therapy follow-up and surveillance were 
undertaken by their respective attending surgeons or oncologists and suspected 
recurrences were based on increasing or elevated CEA levels and/ or suspicious 
findings on follow-up CT imaging.  
The surveillance CECT imaging as well as CEA measurement were performed 
in the patients’ respective hospitals.  All CECT scans were reported by qualified 
radiologists and the CEA measurement were performed using immunoassay method 
with the normal values ranging from < 2.5 to 5.0 ng/ml (in this study, normal value 
was taken as ≤ 3.0 ng/ml). CEA and CECT investigations were performed at the 
intervals of 5 to 12 weeks before PET-CT, with mean durations of 10 weeks. 
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4.2 STUDY DESIGN: 
A retrospective observational study was designed and performed in 
Department of Nuclear Medicine, National Cancer Institute, Putrajaya, Malaysia from 
January to December 2014 to recruit all consecutive patients who fulfilled the 
inclusion and exclusion criteria. The patients were referred from all states in Malaysia 
except for the northern states of Pulau Pinang, Kedah and Perlis.  
Patients who were involved in this study did not require additional procedure 
other than the routine PET-CT imaging, which was conducted in accordance to 
standard operative procedure of the department. Data collection was done and kept in 
a computer database that was accessible solely by the study investigators. This study 
received ethical approval from Medical Research and Ethics Committee (MREC), 
National Institute of Health, Malaysia as well as Jawatankuasa Etika Penyelidikan 
(Manusia) JEPeM, Universiti Sains Malaysia to access the patients’ clinical data. 
Sample size calculation was performed using the following equation for 
dichotomous endpoints, one sample study (Rosner, 2011).  
𝑁 =  𝑝!𝑞! 𝑧!!! ! + 𝑧!!! !!!!!!!!
!
𝑝! − 𝑝! !  𝑞! = 1− 𝑝!  𝑞! = 1− 𝑝!  
p0 = proportion (incidence) of population  
p1 = proportion (incidence) of study group  
N = sample size for study group  
α = probability of type I error (usually 0.05)  
β = probability of type II error (usually 0.2)  
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z = critical Z value for a given α or β 
 
Proportion (recurrence rate) of this study group was 40.6%; proportion 
(recurrence rate) of Malaysian population from previous study was 26% (Rashid et al., 
2009). Hence, the calculated sample size was 76 subjects in order to yield study 
power of 80%. Post-hoc calculation using the following equation demonstrated that 
power of current study (with sample size of 69 subjects) was 76.4%. 
 
𝑃𝑜𝑤𝑒𝑟 =  Φ 𝑁 ∗ 𝑃! − 𝑃! !𝑃! ∗ 𝑄! − 𝑧!!! !𝑃! ∗ 𝑄!𝑃! ∗ 𝑄!  
𝑄! = 1− 𝑃!  𝑄! = 1− 𝑃!  
P0 = proportion (incidence) of population  
P1 = proportion (incidence) of study group  
N = sample size for study group  
α = probability of type I error (usually 0.05)  
z = critical Z value for a given α or β  
Φ() = function converting a critical Z value to power 
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4.3 PET-CT IMAGING: 
Patients were instructed to reduce strenuous exercise for 24 hours and to fast 
for at least 6 hours prior to the procedure. Fasting glucose testing was performed 
using capillary blood and the preferred glucose level to perform PET-CT scans was < 
8.3 mmol/L. If glucose was > 8.3 but < 11.0 mmol/L, subcutaneous rapid acting 
insulin (Actrapid) would be injected but the FDG injection would be delayed for 2 
hours. PET-CT would be postponed if fasting glucose level exceeded 11.0 mmol/L. 
Diabetic patients on insulin therapy were required to omit the morning dose on the 
day of procedure. Once ensuring acceptable glucose level, FDG activity of 5 MBq/kg 
was administered intravenously by a trained technologist while the patients rested in a 
warm, dimly lit room. Imaging was done after a lead-time of 45 to 60 minutes and it 
was performed without intravenous or oral CT contrast. 
An integrated PET-CT system (Discovery ST, GE Medical System, 
Milwaukee, USA) was used for imaging all the patients. Whole-body PET-CT 
acquisition was started with CT scan from the head to the mid-thighs (60mAs, 140kV) 
during current breathing. This was followed immediately by two-dimensional PET 
scan from head to the mid-thighs as well (7 fields of view, 15cm per field, 4 minutes 
emission scan per table position, 3.3mm slice thickness). PET data with and without 
CT attenuation correction was reconstructed by filtered back-projection and ordered-
subset expectation-maximization (OS-EM) (two iterations, 15 subsets and matrix of 
128×128).  
Attenuation corrected PET, CT and combined PET-CT images were displayed 
on a dedicated workstation running Advantage version 4.2 software (GE Medical 
System, Milwaukee, USA). The images were reviewed by an experienced nuclear 
medicine physician using visual assessment and semiquantitative measurement of 
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FDG uptake using maximum standardized uptake values (SUVmax). The physician 
was not blinded to patients’ clinical history. 
 
4.4 REFERENCE STANDARD: 
After six months of PET-CT studies, patients’ clinical diagnosis was retrieved 
through the referring physicians from the respective hospitals.  
1. Recurrence was defined as positive clinical diagnosis of recurrent lesions, which 
was based on histopathology or clinical, and imaging follow up. In patients 
without histopathology confirmation, progression of disease or response of 
disease to treatment was considered as confirmatory of recurrence. 
2. No recurrence was defined as absence of clinical evidence of recurrence based on 
histopathology or clinical and imaging follow up. 
 
4.5 STATISTICAL ANALYSIS: 
The data was analysed with IBM SPSS Statistics software version 22.0. Mean 
CEA levels were compared using independent T-test. P-value of < 0.05 was 
considered to be statistically significant.  
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4.6 DEFINITION OF VARIABLES: 
1. Positive PET-CT: Non-physiological focal FDG uptake more intense than 
background FDG activity that is suggestive of recurrent colorectal cancer. Liver 
FDG activity was considered as background activity to differentiate benign from 
malignant lesions. CT appearance of the lesions was also considered in 
distinguishing benign from malignant lesions. 
2. Negative PET-CT: Physiological FDG metabolism in various organs such as brain, 
heart, liver, urinary tract and diffuse bowel uptake. FDG hypermetabolism that 
was due to inflammatory process or other alternative diagnoses as evidenced by 
CT characteristics of the lesions, was also considered negative. 
3. True positive PET-CT: Positive PET-CT results that were substantiated by 
positive clinical diagnosis of recurrent CRC. 
4. False positive PET-CT: Positive PET-CT results but recurrence was excluded by 
histopathology, clinical or imaging follow-up. 
5. True negative PET-CT: Negative PET-CT results with no evidence of disease 
recurrence at the end of follow-up period. 
6. False negative PET-CT: Negative PET-CT results but recurrence was confirmed 
subsequently by histopathology, clinical or imaging follow-up. 
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4.7 FLOW CHART OF STUDY METHODOLOGY 
 
 
  
PET-CT database was screened for eligible patients: 
Inclusion criteria: 
1. Histologically proven CRC patients post primary treatment with curative intent.  
2. Suspected recurrence due to abnormal CEA or imaging. 
Exclusion criteria: 
1. Distant metastases at presentation. 
2. Recent chemotherapy or surgery less than 1 month, recent radiotherapy less than 3 
months. 
3. History of other primary malignancies. 
Study received ethical approval from MREC, KKM and JePEM, USM 
Patients’ demographic and medical data were retrieved from medical records 
of Department of Nuclear Medicine, IKN, Putrajaya. 
PET-CT images were reviewed by a dedicated senior nuclear medicine consultant. 
Patients’ follow up information was retrieved from the patients’ referring 
physicians to ascertain the final diagnoses. 
Statistical analysis was performed using SPSS software. 
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CHAPTER 5 
RESULTS 
 
5.1 PATIENT RECRUITMENT: 
Total of 85 eligible patients were recruited, however 19 patients were 
excluded from data analysis because their medical records were unavailable to the 
investigator or the patients had discontinued their follow up at their respective 
hospitals.  
 
 
 
 
 
 
 
 
 
 
At the end of at least six months of follow-up period, 28/69 patients (40.6%) 
were diagnosed to have recurrent CRC based on either histopathology or clinical and 
imaging follow-up.  
 
 
 
 
Number of eligible patients recruited = 85 
Number of patients excluded due to 
incomplete clinical data = 16 (18.8%) 
Number of patients included in 
statistical analysis = 69 (81.2%) 
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5.2 DEMOGRAPHIC CHARACTERISTICS: 
 The mean age of the patients was 59.6 years old (range 38 – 79 years old). 
There was slight male preponderance (male: female ratio of 1.46: 1). Percentages of 
Malay and Chinese patients were similar (40.6% and 42.0% respectively). The 
patients’ demographic information was summarised in Table 5.1. 
 
Table 5.1 Summary of patients’ demographic characteristics. 
Age, years (mean, SD) 59.57 (11.29) 
Gender (N, %) 
Male  
Female  
 
41 (59.4%) 
28 (40.6%) 
Ethnic Group (N, %) 
Malay  
Chinese  
Indian  
 
28 (40.6%) 
29 (42.0%) 
12 (17.4%) 
SD, standard deviation. 
  
